Global sites

Global sites

Unlicensed Medicines

Post Trial Access

Service Information

Our unique experience enables us to support pharmaceutical and biotech companies with continuity of patient access from clinical trials through to commercial availability in a more efficient and cost-effective way than a standard open-label trial extension.

Ahead of commercial launch, we provide guidance to ensure the exit strategy for the trial allows for access to medicine on an unlicensed basis outside of the clinical trial environment. This enables continuation of care for patients and a cost-effective solution for pharmaceutical and biotech companies.